Secondary glaucoma in CAPN5-associated neovascular inflammatory vitreoretinopathy

Abdourahman Cham,1,2 Mayank Bansal,3 Himanshu K Banda,4 Young Kwon,1 Paul S Tlucek,1 Alexander G Bassuk,5 Stephen H Tsang,6,7 Warren M Sobol,8 James C Folk,1 Steven Yeh,4 Vinit B Mahajan1,2 1Department of Ophthalmology and Visual Sciences, 2Omics Laboratory, University of Iowa, Iowa City, IA, USA;...

Full description

Bibliographic Details
Main Authors: Cham A, Bansal M, Banda HK, Kwon Y, Tlucek PS, Bassuk AG, Tsang SH, Sobol WM, Folk JC, Yeh S, Mahajan VB
Format: Article
Language:English
Published: Dove Medical Press 2016-06-01
Series:Clinical Ophthalmology
Subjects:
Online Access:https://www.dovepress.com/secondary-glaucoma-in-capn5-associated-neovascular-inflammatory-vitreo-peer-reviewed-article-OPTH
_version_ 1818694620783050752
author Cham A
Bansal M
Banda HK
Kwon Y
Tlucek PS
Bassuk AG
Tsang SH
Sobol WM
Folk JC
Yeh S
Mahajan VB
author_facet Cham A
Bansal M
Banda HK
Kwon Y
Tlucek PS
Bassuk AG
Tsang SH
Sobol WM
Folk JC
Yeh S
Mahajan VB
author_sort Cham A
collection DOAJ
description Abdourahman Cham,1,2 Mayank Bansal,3 Himanshu K Banda,4 Young Kwon,1 Paul S Tlucek,1 Alexander G Bassuk,5 Stephen H Tsang,6,7 Warren M Sobol,8 James C Folk,1 Steven Yeh,4 Vinit B Mahajan1,2 1Department of Ophthalmology and Visual Sciences, 2Omics Laboratory, University of Iowa, Iowa City, IA, USA; 3Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India; 4Department of Ophthalmology, Emory University School of Medicine, Atlanta, GA, 5Department of Pediatrics, University of Iowa, Iowa City, IA, 6Barbara and Donald Jonas Laboratory of Stem Cells and Regenerative Medicine and Bernard and Shirlee Brown Glaucoma Laboratory, Department of Pathology and Cell Biology, Institute of Human Nutrition, College of Physicians and Surgeons, Columbia University, 7Edward S Harkness Eye Institute, New York-Presbyterian Hospital, New York, NY, 8Retina Physicians & Surgeons, Inc., Dayton, OH, USA Objective: The objective of this study was to review the treatment outcomes of patients with secondary glaucoma in cases of autosomal dominant neovascular inflammatory vitreoretinopathy (ADNIV), a hereditary autoimmune uveitis due to mutations in CAPN5. Patients and methods: A retrospective, observational case series was assembled from ADNIV patients with secondary glaucoma. The main outcome measures were intraocular pressure (IOP), visual acuity, use of antiglaucoma medications, ocular surgeries, and adverse outcomes. Perimetry and optic disk optical coherence tomography (OCT) were also analyzed. Results: Nine eyes of five ADNIV patients with secondary glaucoma were reviewed. Each received a fluocinolone acetonide (FA) implant for the management of posterior uveitis. Following implantation, no eyes developed neovascular glaucoma. Five eyes (in patients 1, 2, and 5) required Ahmed glaucoma valve surgery for the management of steroid-responsive glaucoma. Patient 2 also developed angle closure with iris bombe and underwent laser peripheral iridotomy. Patient 4 had both hypotony and elevated IOP that required periodic antiglaucoma medication in the FA-implanted eye. Patient 3 did not develop steroid-response glaucoma in either eye. Optic disk examinations were obscured by fibrosis and better assessed with OCT. Conclusion: ADNIV patients show combined mechanism secondary glaucoma best assessed by OCT of the optic disk. The FA implants have reduced uveitic and neovascular glaucoma. Nevertheless, IOP management remains complex due to steroid-response glaucoma, angle closure glaucoma, and hypotony. Keywords: ADNIV, CAPN5, calpain-5, fluocinolone acetonide, secondary glaucoma, uveitis
first_indexed 2024-12-17T13:32:29Z
format Article
id doaj.art-0a9207be1b6a43b7b334aaf7a0e786d8
institution Directory Open Access Journal
issn 1177-5483
language English
last_indexed 2024-12-17T13:32:29Z
publishDate 2016-06-01
publisher Dove Medical Press
record_format Article
series Clinical Ophthalmology
spelling doaj.art-0a9207be1b6a43b7b334aaf7a0e786d82022-12-21T21:46:31ZengDove Medical PressClinical Ophthalmology1177-54832016-06-012016Issue 11187119727621Secondary glaucoma in CAPN5-associated neovascular inflammatory vitreoretinopathyCham ABansal MBanda HKKwon YTlucek PSBassuk AGTsang SHSobol WMFolk JCYeh SMahajan VBAbdourahman Cham,1,2 Mayank Bansal,3 Himanshu K Banda,4 Young Kwon,1 Paul S Tlucek,1 Alexander G Bassuk,5 Stephen H Tsang,6,7 Warren M Sobol,8 James C Folk,1 Steven Yeh,4 Vinit B Mahajan1,2 1Department of Ophthalmology and Visual Sciences, 2Omics Laboratory, University of Iowa, Iowa City, IA, USA; 3Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India; 4Department of Ophthalmology, Emory University School of Medicine, Atlanta, GA, 5Department of Pediatrics, University of Iowa, Iowa City, IA, 6Barbara and Donald Jonas Laboratory of Stem Cells and Regenerative Medicine and Bernard and Shirlee Brown Glaucoma Laboratory, Department of Pathology and Cell Biology, Institute of Human Nutrition, College of Physicians and Surgeons, Columbia University, 7Edward S Harkness Eye Institute, New York-Presbyterian Hospital, New York, NY, 8Retina Physicians & Surgeons, Inc., Dayton, OH, USA Objective: The objective of this study was to review the treatment outcomes of patients with secondary glaucoma in cases of autosomal dominant neovascular inflammatory vitreoretinopathy (ADNIV), a hereditary autoimmune uveitis due to mutations in CAPN5. Patients and methods: A retrospective, observational case series was assembled from ADNIV patients with secondary glaucoma. The main outcome measures were intraocular pressure (IOP), visual acuity, use of antiglaucoma medications, ocular surgeries, and adverse outcomes. Perimetry and optic disk optical coherence tomography (OCT) were also analyzed. Results: Nine eyes of five ADNIV patients with secondary glaucoma were reviewed. Each received a fluocinolone acetonide (FA) implant for the management of posterior uveitis. Following implantation, no eyes developed neovascular glaucoma. Five eyes (in patients 1, 2, and 5) required Ahmed glaucoma valve surgery for the management of steroid-responsive glaucoma. Patient 2 also developed angle closure with iris bombe and underwent laser peripheral iridotomy. Patient 4 had both hypotony and elevated IOP that required periodic antiglaucoma medication in the FA-implanted eye. Patient 3 did not develop steroid-response glaucoma in either eye. Optic disk examinations were obscured by fibrosis and better assessed with OCT. Conclusion: ADNIV patients show combined mechanism secondary glaucoma best assessed by OCT of the optic disk. The FA implants have reduced uveitic and neovascular glaucoma. Nevertheless, IOP management remains complex due to steroid-response glaucoma, angle closure glaucoma, and hypotony. Keywords: ADNIV, CAPN5, calpain-5, fluocinolone acetonide, secondary glaucoma, uveitishttps://www.dovepress.com/secondary-glaucoma-in-capn5-associated-neovascular-inflammatory-vitreo-peer-reviewed-article-OPTHADNIVCAPN5calpain-5Fluocinolone AcetonideSecondary GlaucomaUveitis.
spellingShingle Cham A
Bansal M
Banda HK
Kwon Y
Tlucek PS
Bassuk AG
Tsang SH
Sobol WM
Folk JC
Yeh S
Mahajan VB
Secondary glaucoma in CAPN5-associated neovascular inflammatory vitreoretinopathy
Clinical Ophthalmology
ADNIV
CAPN5
calpain-5
Fluocinolone Acetonide
Secondary Glaucoma
Uveitis.
title Secondary glaucoma in CAPN5-associated neovascular inflammatory vitreoretinopathy
title_full Secondary glaucoma in CAPN5-associated neovascular inflammatory vitreoretinopathy
title_fullStr Secondary glaucoma in CAPN5-associated neovascular inflammatory vitreoretinopathy
title_full_unstemmed Secondary glaucoma in CAPN5-associated neovascular inflammatory vitreoretinopathy
title_short Secondary glaucoma in CAPN5-associated neovascular inflammatory vitreoretinopathy
title_sort secondary glaucoma in capn5 associated neovascular inflammatory vitreoretinopathy
topic ADNIV
CAPN5
calpain-5
Fluocinolone Acetonide
Secondary Glaucoma
Uveitis.
url https://www.dovepress.com/secondary-glaucoma-in-capn5-associated-neovascular-inflammatory-vitreo-peer-reviewed-article-OPTH
work_keys_str_mv AT chama secondaryglaucomaincapn5associatedneovascularinflammatoryvitreoretinopathy
AT bansalm secondaryglaucomaincapn5associatedneovascularinflammatoryvitreoretinopathy
AT bandahk secondaryglaucomaincapn5associatedneovascularinflammatoryvitreoretinopathy
AT kwony secondaryglaucomaincapn5associatedneovascularinflammatoryvitreoretinopathy
AT tlucekps secondaryglaucomaincapn5associatedneovascularinflammatoryvitreoretinopathy
AT bassukag secondaryglaucomaincapn5associatedneovascularinflammatoryvitreoretinopathy
AT tsangsh secondaryglaucomaincapn5associatedneovascularinflammatoryvitreoretinopathy
AT sobolwm secondaryglaucomaincapn5associatedneovascularinflammatoryvitreoretinopathy
AT folkjc secondaryglaucomaincapn5associatedneovascularinflammatoryvitreoretinopathy
AT yehs secondaryglaucomaincapn5associatedneovascularinflammatoryvitreoretinopathy
AT mahajanvb secondaryglaucomaincapn5associatedneovascularinflammatoryvitreoretinopathy